Developability and Formulation of therapeutic proteins and antibodies
The successful development of biotherapeutics (e.g. antibodies) is not limited to the optimization of their biological activity, but also relies on their industrial “developability” potential. Developability criteria encompass for instance their ease of manufacture, stability during storage, and the absence of non-specific interactions. Misbehavior of drug candidates in developability assays is associated to detrimental consequences for the successful development of bioprocesses and stable drug formulations, and can even compromise drug pharmacokinetics.
In our lab, we develop new tools to enable the prediction of the developability potential of drug candidates as well as the acceleration of the formulation design.
Contacts
Marianna Carone, Isabel Waibel
Key publications
external page H.Narayanan et al. "Design of Biopharmaceutical Formulations Accelerated by Machine Learning" Mol. Pharm., 2021
external page M.R.G.Kopp et al. "An accelerated surface-mediated stress assay of antibody instability for developability studies" mAbs, 2020
external page F.Grigolato et al. "Synergistic Effects of Flow and Interfaces on Antibody Aggregation" Biotechnology and Bioengineering, 2020